IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Bellevue Group AG

Bellevue Group AG boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 41.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 129,827 shares of the medical research company's stock after buying an additional 37,744 shares during the quarter. Bellevue Group AG owned 0.07% of IQVIA worth $30,765,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. PGGM Investments increased its stake in IQVIA by 55.8% in the second quarter. PGGM Investments now owns 12,073 shares of the medical research company's stock worth $2,553,000 after purchasing an additional 4,326 shares during the period. Simplify Asset Management Inc. lifted its holdings in IQVIA by 67.8% during the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company's stock valued at $2,284,000 after buying an additional 3,894 shares in the last quarter. Raymond James & Associates grew its stake in IQVIA by 0.7% in the 2nd quarter. Raymond James & Associates now owns 800,374 shares of the medical research company's stock worth $169,231,000 after acquiring an additional 5,417 shares in the last quarter. Versor Investments LP bought a new stake in shares of IQVIA during the third quarter valued at approximately $1,328,000. Finally, Gradient Investments LLC grew its stake in IQVIA by 15.6% in the second quarter. Gradient Investments LLC now owns 45,401 shares of the medical research company's stock worth $9,600,000 after purchasing an additional 6,134 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Royal Bank of Canada restated an "outperform" rating and set a $270.00 price target on shares of IQVIA in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered their price target on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Robert W. Baird dropped their target price on IQVIA from $256.00 to $223.00 and set a "neutral" rating on the stock in a research report on Friday, November 1st. Finally, Redburn Atlantic assumed coverage on IQVIA in a research report on Monday, October 14th. They issued a "buy" rating and a $276.00 price target for the company. Five equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Stock Performance

Shares of IQVIA stock traded down $0.59 during trading on Friday, hitting $200.84. 513,717 shares of the company's stock were exchanged, compared to its average volume of 2,104,433. The stock has a market capitalization of $36.45 billion, a price-to-earnings ratio of 26.36, a PEG ratio of 2.07 and a beta of 1.51. The business has a 50-day simple moving average of $218.67 and a 200-day simple moving average of $226.17. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.